ARCHIVES

Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials

This article is from The Cancer Letter archive.

Vol. 29 No. 28 | July 11, 2003

Download PDF Visit The Full Archive

Related Articles

FDA Approves Velcade Injection In Mantle Cell Lymphoma

October 31, 2014

Amgen Agrees To Buy Immunex For $16 Billion In Stock And Cash.

January 25, 2002

DCBD Okays Concept For Molecular Probes In Colon Cancer, Two Other Organ Systems Generated Projects

July 4, 1986

HPV Vaccine Cervarix Active In 100% Of Women In Study

July 27, 2007

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

January 8, 1999

Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage

May 31, 2013